AstraZeneca has gained approval from the European Commission for its oral therapy, Tagrisso (osimertinib), to treat adults with NSCLC.
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical have signed an exclusive agreement for RPT904 to treat various allergic conditions.
Aclara Resources is raising $25m through a non-brokered private placement to fund its Carina project in Brazil.